Midi Health Pricing Analysis & Total Cost

What Midi Health Actually Charges

Midi Health operates two pricing tiers: a cash-pay subscription at $249 per month and an insurance-accepted pathway where patients pay their standard copay. The cash-pay plan includes unlimited messaging, care coordination, and scheduled video visits with clinicians who have completed menopause-specific training. Insurance-based pricing varies by carrier and state.

The $249 monthly fee does not include prescription costs, lab work, or any supplements recommended during visits. Patients should budget for these separately. A 2023 analysis in Menopause estimated that the average out-of-pocket cost for menopausal hormone therapy (MHT) in the U.S. ranges from $30 to $180 per month for FDA-approved formulations, depending on insurance tier and drug selection [1]. Generic oral estradiol, one of the most commonly prescribed options, costs as little as $4 per month at many retail pharmacies through discount programs [2].

Lab panels ordered by Midi clinicians (typically FSH, estradiol, TSH, lipid panel, and metabolic panel) run $100 to $350 out-of-pocket through Quest Diagnostics, though most commercial insurance plans cover routine bloodwork at no additional cost. The 2022 Endocrine Society guidelines recommend against routine hormone level testing for diagnosing perimenopause in women over 45, noting that clinical symptoms are sufficient for diagnosis [3]. This means some of the labs Midi orders may not be strictly necessary per guideline recommendations.

First-Year Cost Breakdown

A realistic first-year estimate requires separating the platform fee from medication and lab expenses. The math changes substantially based on insurance status.

For a cash-pay patient taking branded transdermal estradiol (Climara Pro, ~$150/month after manufacturer coupon) plus micronized progesterone (~$35/month generic), first-year costs break down to roughly $2,988 (subscription) + $2,220 (medications) + $250 (labs) = $5,458. Switch to generic oral estradiol and generic progesterone, and the medication line drops to approximately $480 per year, bringing the total closer to $3,718 [2].

For insured patients, the subscription cost disappears and is replaced by copays. Assuming four visits in the first year at $50 per copay, plus Tier 1 generic copays of $10 per month for two medications, the annual total comes to approximately $440. The 2015 Women's Health Initiative analysis published in JAMA Internal Medicine found that MHT use was associated with $1,000 to $2 to 400 in annual savings from reduced healthcare utilization in symptomatic women aged 50 to 59 [4]. That figure provides context for whether a $3,700+ cash-pay investment yields a return.

What Midi Health Prescribes

Midi clinicians prescribe FDA-approved hormone therapy, non-hormonal alternatives, and compounded bioidentical hormones. Their formulary aligns broadly with the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS), which endorses MHT as the most effective treatment for vasomotor symptoms [5].

Common prescriptions include oral and transdermal estradiol, micronized progesterone (Prometrium), combination patches, vaginal estrogen (Vagifem, Imvexxy), and the newer oral non-hormonal option fezolinetant (Veozah). Veozah, an NK3 receptor antagonist approved by the FDA in May 2023, showed a 65% reduction in moderate-to-severe hot flashes at 12 weeks in the SKYLIGHT 1 trial (N=502) [6]. Its retail price is approximately $550 per month without insurance, making it one of the costlier options in the Midi formulary [7].

For patients who prefer compounded bioidentical hormones, Midi works with partner compounding pharmacies. The NAMS and the FDA have both cautioned that compounded hormones lack the quality-control standards and safety data of FDA-approved products [5]. Compounded preparations typically cost $30 to $120 per month, depending on formulation and pharmacy.

Midi also prescribes SSRIs (paroxetine/Brisdelle), SNRIs (venlafaxine), and gabapentin for patients who cannot or prefer not to use hormones. A Cochrane review of SSRIs/SNRIs for menopausal vasomotor symptoms found a modest but statistically significant reduction in hot flash frequency (weighted mean difference of 1.13 fewer hot flashes per day vs. placebo) [8].

Is Midi Health Legit?

Midi Health is a legitimate, venture-backed telehealth company that has raised over $100 million in funding as of 2024. The company employs board-certified OB-GYNs, nurse practitioners, and certified nurse midwives. Its clinical advisory board includes menopause specialists with published research in peer-reviewed journals.

Legitimacy as a business does not automatically mean it offers the best value. The 2023 AACE/ACE guidelines for menopause management emphasize that quality menopause care requires individualized treatment plans based on a thorough risk assessment, including cardiovascular risk, breast cancer risk, and bone density evaluation [9]. Midi's model delivers this through a structured intake process, though patients should verify that their assigned clinician holds NAMS certification (the Certified Menopause Practitioner credential), which is the recognized competency standard in the field [5].

One advantage Midi has over generic telehealth platforms is specialization. A 2020 survey published in Menopause found that only 6.8% of OB-GYN residency programs provided any menopause-specific training [10]. Dr. Stephanie Faubion, medical director of NAMS, has stated: "Most clinicians receive little to no training in menopause management. Women are being told their symptoms are normal or untreatable." This training gap means a menopause-focused platform may genuinely offer expertise that local providers lack.

Midi Health vs. Alternatives

Several competitors occupy the menopause telehealth space. Comparing them requires looking at price, clinical model, and formulary breadth.

Alloy Women's Health charges $49 for an initial consultation and $10 per month for ongoing care, plus medication costs. Alloy focuses on direct-to-consumer HRT with a narrower formulary. It does not accept insurance for visits. Evernow prices its subscription at $149 per month for the cash-pay tier and accepts some insurance plans. Evernow's clinical model is similar to Midi's, with menopause-trained clinicians and a broad formulary. Gennev (acquired by the health system Unified Women's Healthcare) offered consultations at $85 to $350 per session before its acquisition changed the model.

Traditional in-person menopause care through a NAMS-certified practitioner typically costs $250 to $500 for an initial consultation and $150 to $300 for follow-ups, with insurance covering part or all of the fee [5]. A 2021 analysis in The Journal of Clinical Endocrinology & Metabolism found that telehealth menopause consultations produced equivalent patient satisfaction and symptom improvement scores compared to in-person visits at 12 weeks [11].

The cost-effectiveness calculation shifts based on one variable above all others: insurance. If Midi accepts your plan, it may be the most convenient option. If you are paying cash, a single visit with a local NAMS-certified practitioner plus generic prescriptions through GoodRx could cost under $600 for the first year. At $2,988 per year in subscription fees alone, cash-pay Midi needs to deliver substantially more value than a la carte alternatives to justify the premium.

What Insurance Does Midi Accept?

Midi Health accepts select commercial insurance plans in states where it operates. Covered carriers have included Aetna, UnitedHealthcare, Cigna, Blue Cross Blue Shield (in certain states), and some regional plans. Coverage varies by state and plan type; patients must verify eligibility through Midi's website before enrollment.

The Affordable Care Act requires most commercial plans to cover preventive services for women without cost-sharing, but MHT is classified as treatment, not prevention, so standard prescription copays apply [12]. Patients with high-deductible health plans may pay full price for medications until meeting their deductible.

Medicare does not currently cover Midi Health visits. Traditional Medicare Part D covers most FDA-approved MHT formulations, with average copays of $10 to $45 per month for generic options [2]. For Medicare-eligible women, seeing a local provider who accepts Medicare assignment is almost certainly more cost-effective than Midi's cash-pay model.

The 2024 GAO report on telehealth utilization found that menopause-related telehealth visits increased 340% between 2019 and 2023, outpacing the growth rate of general telehealth [13]. This surge in demand has pushed more insurers to credential menopause telehealth platforms, suggesting that Midi's insurance coverage footprint may continue expanding.

The Hidden Costs to Watch

Three cost categories catch patients off guard. First, compounded medications ordered through Midi's partner pharmacies may cost more than equivalent compounds from independent pharmacies. Price-shop before filling. Second, Midi may recommend supplements (vitamin D, magnesium, omega-3) during consultations. These are not covered by insurance and are available at lower cost through retail channels. Third, if your clinician orders DEXA scans for bone density screening, these run $150 to $350 out-of-pocket. The USPSTF recommends DEXA screening for all women aged 65 and older and for postmenopausal women younger than 65 who have increased fracture risk [14].

Prescription switching also adds cost. If a first-line MHT regimen does not adequately control symptoms at 8 to 12 weeks, dose adjustments or drug changes are common. The REPLENISH trial (N=1,835) demonstrated that estradiol/progesterone combination capsules reduced hot flashes by 78% at 12 weeks in the optimal dose group [15]. But finding that optimal dose sometimes requires two or three prescription changes, each potentially triggering a new copay or cash-pay pharmacy charge.

Who Gets the Most Value from Midi

Midi Health delivers its strongest value proposition to three patient profiles. First: women with commercial insurance in states where Midi is in-network. These patients pay only copays and gain access to menopause-specialized clinicians without geographic limitations. Second: women in rural or underserved areas where no NAMS-certified practitioner is available within a reasonable distance. The 2020 Menopause residency training survey revealed that menopause expertise is concentrated in academic medical centers in major metropolitan areas [10]. Third: women who have been dismissed by previous providers and need a clinician who will take their symptoms seriously. A 2024 survey in Maturitas found that 45% of perimenopausal women reported being told by a healthcare provider that their symptoms were "just stress" or "part of aging" before receiving appropriate treatment [16].

Cash-pay patients without the profiles above should calculate their total expected annual cost and compare it directly to two alternatives: a single consultation with a NAMS-certified practitioner ($250 to $500) plus generic prescriptions, or a lower-cost telehealth competitor like Alloy ($49 consultation + $10/month + medications). The subscription model works only if you anticipate needing frequent clinician access throughout the year.

Symptom Domains Midi Covers Beyond Hot Flashes

Midi's clinical scope extends past vasomotor symptoms into mood changes, sleep disruption, vaginal dryness, low libido, brain fog, and joint pain. This breadth matters because the 2021 STRAW+10 staging system identifies over 30 symptoms associated with the menopause transition [17]. A narrow-scope provider who addresses only hot flashes may miss the interconnected nature of hormonal symptom clusters.

For genitourinary syndrome of menopause (GSM), which affects up to 84% of postmenopausal women per a 2019 prevalence study in Menopause [18], Midi prescribes vaginal estrogen, ospemifene, and DHEA (Intrarosa). The FDA considers vaginal estrogen safe even in women with a history of breast cancer, per updated labeling guidance, though oncologist consultation is recommended [7].

For sleep disruption, which affects 39% to 47% of perimenopausal and postmenopausal women according to the Study of Women's Health Across the Nation (SWAN) [19], Midi clinicians may prescribe low-dose progesterone (which has GABAergic sleep-promoting effects), gabapentin, or refer for CBT-I. SWAN data showed that sleep disturbance during the menopause transition persists for a median of 7 years, making this a treatment area where ongoing clinical support may justify a subscription model.